Stock HNSBF HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Hansa Biopharma AB OTC Markets

Equities

HNSBF

SE0002148817

Market Closed - OTC Markets
Other stock markets
 07:00:14 14/03/2024 pm IST 		5-day change 1st Jan Change
2.93 USD -9.98% Intraday chart for Hansa Biopharma AB -.--% +29.82%
18/04 Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
18/04 Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Hansa Biopharma AB

Price target over the last 5 years

History of analyst recommendation changes

85ec66af9.KMAa2JYvR6qqBQrB-pv8XrHcBidXCLoEWTxoDcGtMME.Zrp1l95Xcdz4YEuLtNzOBsnvZ3I6bf0yH0g_b43aUfhOi0i502cN9cZCMg~af49abfed50049a0c1760bd5b67ac699

Analyst Recommendations on Hansa Biopharma AB

Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
43.62 SEK
Average target price
105 SEK
Spread / Average Target
+140.72%
High Price Target
175 SEK
Spread / Highest target
+301.19%
Low Price Target
57 SEK
Spread / Lowest Target
+30.67%

Consensus detail

Consensus revision (last 18 months)

Ratings for Hansa Biopharma AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. HNSBF Stock
  5. Consensus Hansa Biopharma AB